

May 30, 2025

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sirs,

Sub: Outcome of the Board Meeting held on Friday, May 30, 2025

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

The Board of Directors of the Company at its meeting held today i.e., May 30, 2025, has *inter-alia*:

1. Approved the Audited financial results of the Company for the quarter and year ended March 31, 2025. The said Audited financial results together with the Audit report of the Statutory Auditors dated May 30, 2025 are enclosed herewith.
2. Recommended Dividend of Rs. 32/- per equity share for the financial year 2024-25.

We also confirm that the Statutory Auditor's Report is with unmodified opinion in respect of the Audited financial results of the Company for the financial year ended March 31, 2025.

The press release with regard to the same is also enclosed herewith.

The meeting commenced at 2:30 P.M. and concluded at 5:00 P.M. (IST).

Please take the same on record.

For **AstraZeneca Pharma India Limited**



Manasa. R
Company Secretary



Encl: As above

Statement of financial results for the quarter and year ended 31 March 2025

'Rs in millions except for earnings per share data						
SI No.	Particulars	Quarter ended 31/03/2025	Quarter ended 31/12/2024	Quarter ended 31/03/2024	Year ended 31/03/2025	Year ended 31/03/2024
		Refer Note 4	Unaudited	Refer Note 4	Audited	Audited
1	Income					
	a) Revenue from operations	4,804.8	4,402.9	3,832.0	17,162.9	12,955.3
	b) Other income	161.5	79.8	86.6	406.3	348.0
	Total income	4,966.3	4,482.7	3,918.6	17,569.2	13,303.3
2	Expenses					
	(a) Cost of materials consumed	942.5	698.8	336.2	2,871.3	1,290.2
	(b) Purchase of stock-in-trade	2,878.6	2,287.6	749.8	10,088.2	4,993.1
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,225.0)	(516.1)	1,049.5	(3,329.4)	(337.7)
	(d) Employee benefit expense	660.7	623.7	579.8	2,574.4	2,414.5
	(e) Depreciation and amortisation expense	176.9	90.7	37.6	399.9	149.4
	(f) Allowance for expected credit loss (net)	(9.4)	(1.7)	41.8	6.6	54.4
	(g) Selling, marketing and distribution expense	220.2	227.4	211.4	848.7	860.1
	(h) Other expenses	473.5	313.3	369.6	1,563.4	1,836.2
	(i) Finance costs	6.8	3.3	(0.7)	14.6	12.0
	Total expenses	4,124.8	3,727.0	3,375.0	15,037.7	11,272.2
3	Profit before exceptional items and tax (1-2)	841.5	755.7	543.6	2,531.5	2,031.1
4	Add/(Less): Exceptional items (Refer Note 3)	(56.8)	(335.5)	-	(967.9)	164.3
5	Profit / (loss) before tax (3+4)	784.7	420.2	543.6	1,563.6	2,195.4
6	Tax expense					
	(a) Current tax	229.2	121.7	155.2	601.0	535.5
	(b) Tax expense for prior years	-	-	-	4.4	53.8
	(c) Deferred tax charge / (credit)	(27.0)	(10.0)	(6.4)	(199.2)	(9.0)
	Total tax expense	202.2	111.7	148.8	406.2	580.3
7	Profit / (loss) after tax (5-6)	582.5	308.5	394.8	1,157.4	1,615.1
8	Other comprehensive income/ (loss)					
	Items that will not be reclassified to profit or loss					
	(a) Re-measurement gains / (losses) on post employment benefit obligations	19.6	(23.0)	2.7	(15.6)	13.3
	(b) Income tax effect on above	(5.0)	5.8	(0.7)	3.9	(3.3)
	Other comprehensive income/ (loss), net of income tax	14.6	(17.2)	2.0	(11.7)	10.0
9	Total comprehensive income / (loss) for the period (7+8)	597.1	291.3	396.8	1,145.7	1,625.1
10	Paid-up equity share capital (Face value of Rs 2/- per equity share)	50.0	50.0	50.0	50.0	50.0
11	Other Equity	-	-	-	7,653.5	7,069.2
12	Earnings per equity share of Rs 2/- each (basic and diluted)	23.30	12.34	15.79	46.30	64.60



Initialled For
Identification
Purpose Only

Statement of financial results for the quarter and year ended 31 March 2025

Notes:

- 1 The Statements of Financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (Companies (Indian Accounting Standards) Rules, 2015 (as amended)) and other accounting principles generally accepted in India.
- 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided.
- 3 **Exceptional items**
 - a Exceptional items for the year ended 31 March 2025 consists of employee separation cost amounting to Rs. 331.5 Million for restructuring of Biopharmaceuticals Business Unit in line with strategy of the Company to become a specialist focussed organisation, bring innovative medicines faster and transform patient outcome.
 - b During the previous year, the Company had made an announcement to Stock exchanges about its intention to exit the Company's manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. The operations at the manufacturing site is continuing as at March 31, 2025 and is expected to cease during the financial year 2025-26. The Company has estimated and accounted for expense amounting to Rs. 56.8 Million for the quarter ended March 31, 2025 and Rs. 636.4 Million in relation to the closure of manufacturing site, in accordance with the relevant Indian accounting standards.
 - c The Company had entered into an Advance Pricing Agreement with Central Board of Direct Taxation for financial years 2015-2016 to 2019-2020 for which there were certain previously disclosed disputed Transfer Pricing matters consequent to which an amount of Rs. 154.3 Million is disclosed as an exceptional Income for the year ended 31 March 2024.
 - 4 The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of the full financial years and the published unaudited year-to-date figures up to the third quarter of the respective financial years which were subjected to limited review by the statutory auditors.
 - 5 The Board of Directors, at its meeting dated 30 May 2025, have recommended a final dividend of Rs. 32 per equity share aggregating to Rs. 800 Million which is subject to approval of shareholders at the ensuing Annual General Meeting.
 - 6 This Statement of financial results, Statement of assets and liabilities and Statement of cash flows were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 30 May 2025.
 - 7 The Company has decided to change the rounding off principle followed in the Statement of financial results from lakhs of rupees to millions of rupees from the quarter ended 30 June 2024.

**By Order of the Board of Directors
For AstraZeneca Pharma India Limited**

Sanjeev Kumar Panchal
Sanjeev Kumar Panchal
Managing Director

Place: Bengaluru
Date: 30 May 2025




**Initialed For
Identification
Purpose Only**

AstraZeneca Pharma India Limited
 Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli,
 Outer Ring Road, Bangalore 560 045
 CIN: L24231KA1979PLC003563

Statement of assets and liabilities as at 31 March 2025

(Rs. in millions)

Sl.No.	Balance Sheet	As at	As at
		31 March 2025	31 March 2024
		Audited	Audited
	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	278.8	603.7
	(b) Right-of-use assets	357.0	42.0
	(c) Capital work-in-progress	0.0	2.7
	(d) Intangible assets	6.6	21.1
	(e) Financial Assets		
	(i) Loans	1.1	2.7
	(ii) Other financial assets	80.3	24.7
	(f) Current tax assets (net) (non-current)	602.6	526.3
	(g) Deferred tax assets (net)	415.6	212.5
	(h) Other non-current assets	15.7	17.5
	Sub-total - Non-current assets	1,757.7	1,453.2
2	Current assets		
	(a) Inventories	5,485.0	2,278.8
	(b) Financial Assets		
	(i) Trade receivables	1,848.8	1,531.3
	(ii) Cash and cash equivalents	5,361.4	5,055.7
	(iii) Bank balances other than cash and cash equivalents	5.6	2.7
	(iv) Loans	3.0	1.3
	(v) Other financial assets	158.0	178.8
	(c) Other current assets	561.7	278.5
	Sub-total - Current assets	13,423.5	9,327.1
	TOTAL - ASSETS	15,181.2	10,780.3
	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share capital	50.0	50.0
	(b) Other Equity	7,653.5	7,069.2
	Sub-total - Shareholders' funds	7,703.5	7,119.2
2	LIABILITIES		
	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Lease liabilities	294.5	27.8
	(b) Provisions	63.2	62.1
	(c) Other liabilities	90.0	-
	Sub-total - Non-current liabilities	447.7	89.9
3	Current liabilities		
	(a) Financial Liabilities		
	(i) Lease liabilities	62.8	18.1
	(ii) Trade payables		
	Total outstanding dues of micro and small enterprises	25.3	36.1
	Total outstanding dues of creditors other than micro and small enterprises	4,537.7	1,929.0
	(iii) Other financial liabilities	252.7	310.1
	(b) Provisions	1,065.3	434.2
	(c) Current tax liabilities (net)	108.4	66.6
	(d) Other current liabilities	979.8	777.1
	Sub-total - Current liabilities	7,030.0	3,571.2
	TOTAL - EQUITY AND LIABILITIES	15,181.2	10,780.3



Initialled For
Identification
Purpose Only

AstraZeneca Pharma India Limited
 Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli,
 Outer Ring Road, Bangalore 560 045


CIN: L24231KA1979PLC003563

Statement of cash flows for the year ended 31 March 2025

Particulars	(Rs. in millions)	
	Year ended 31 March 2025 Audited	Year ended 31 March 2024 Audited
A) Cash flow from operating activities		
Profit before tax	1,563.6	2,195.4
Non-cash adjustments for :		
Depreciation and amortisation expense	399.9	149.4
(Profit) on sale of property, plant and equipment (net)	(3.2)	(0.3)
Provision for restructuring costs	613.2	-
Provisions no longer required written back	-	(1.8)
Impairment of Other assets	4.6	12.4
Interest income on deposits carried at amortised cost	(315.6)	(325.7)
Employee stock compensation expense	51.4	27.4
Unrealised foreign exchange gain (net)	(7.4)	1.5
Allowance for expected credit loss (net)	6.6	54.4
Finance costs	14.6	12.0
Operating profit before working capital changes	2,327.7	2,124.7
Changes in working capital:		
(Increase) / Decrease in trade receivables	(316.8)	(511.8)
(Increase) / Decrease in inventories	(3,206.2)	(376.7)
(Increase) / Decrease in loans	(0.1)	5.6
(Increase) / Decrease in other financial assets	(52.6)	(62.0)
(Increase) / Decrease in other assets	(282.5)	(12.4)
Increase / (Decrease) in trade payables	2,598.1	(313.7)
Increase / (Decrease) in provisions	3.4	8.8
Increase / (Decrease) in other financial liabilities	(68.2)	(16.0)
Increase / (Decrease) in other liabilities	292.7	(3.5)
Cash generated from operations	1,295.5	843.0
Income taxes paid (net of refund)	(641.9)	(564.3)
Net cash generated from operating activities (A)	653.6	278.7
B) Cash flows from investing activities		
Interest income on bank deposits	318.4	320.9
Purchase of property, plant and equipment and intangible assets	(17.5)	(107.6)
Proceeds from sale of property, plant and equipment	7.1	4.1
Net cash generated from investing activities (B)	308.0	217.4
C) Cash flows from financing activities		
Principal repayment of lease liabilities	(41.3)	(38.6)
Interest paid on lease liabilities	(14.0)	(5.2)
Interest paid - others	(0.6)	-
Dividend paid	(600.0)	(400.0)
Net cash used in financing activities (C)	(655.9)	(443.8)
D) Net increase in cash and cash equivalents (A+B+C)	305.7	52.3
E) Cash and cash equivalents at the beginning of the year	5,055.7	5,003.4
F) Cash and cash equivalents at the end of the year (D+E)	5,361.4	5,055.7



**Initialed For
Identification
Purpose Only**



Price Waterhouse & Co Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of AstraZeneca Pharma India Limited

Report on the Audit of Financial Results

Opinion

1. We have audited the accompanying annual financial results of AstraZeneca Pharma India Limited (hereinafter referred to as the "Company") for the year ended March 31, 2025, and the Statement of assets and liabilities as on that date and the Statement of cash flows as at and for the year ended on that date (the "financial results"), attached herewith, which are included in the accompanying 'Statement of financial results for the quarter and year ended 31 March 2025', 'Statement of assets and liabilities as at 31 March 2025' and 'Statement of cashflows for the year ended 31 March 2025' (together the "Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations') which has been initialed by us for identification purposes.
2. In our opinion and to the best of our information and according to the explanations given to us, the financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income/(loss) and other financial information of the Company for the year ended March 31, 2025 and the Statement of assets and liabilities and the Statement of cash flows as at and for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road, Ulsoor
Bengaluru - 560 008
T: +91 (80) 40794188

Registered office and Head office: Plot No. 56 & 57, Block DN, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

Price Waterhouse & Co Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of AstraZeneca Pharma India Limited

Report on the Financial Results

Page 2 of 3

Board of Directors' Responsibilities for the Financial Results

4. These financial results have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of the financial results that give a true and fair view of the net profit and other comprehensive income/(loss) and other financial information of the Company and the statement of assets and liabilities and the statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the financial results by the Directors of the Company, as aforesaid.
5. In preparing the financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

7. Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.
8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - a) Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



Price Waterhouse & Co Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of AstraZeneca Pharma India Limited

Report on the Financial Results

Page 3 of 3

- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
 - d) Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - e) Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
 10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The Financial Results include the results for the quarter ended March 31, 2025, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/E-300009



Sharmila Ramaswamy
Partner

Membership Number: 215131
UDIN: 25215131BMNPYV5945

Place: Bengaluru
Date: May 30, 2025

AstraZeneca Pharma India Limited marks a consistent 32 % growth as the company announces its annual results for FY 2024-25

Total Revenue from operations is INR 17162.9 Mn - up by 32% and Core EPS announced as INR 46.30

Bengaluru, May 30, 2025: AstraZeneca Pharma India Limited (the Company), a science-led biopharmaceutical company, today announced its full year performance for the financial year April 2024-March 2025. The Company sustained its momentum from previous quarters and recorded a significant year-on-year growth across therapeutic areas, achieving a 32% increase in revenue compared to the same period last year.

Financial performance Summary -

Summary		Q4 Jan'24-Mar'24 (Value in INR Mn)	Full year Apr'23-Mar'24	Q4 Jan'25 – Mar'25 (Value in INR Mn)	Full year Apr'24-Mar'25
Total Revenue from Operation		3832.0	12955.3	4804.8	17162.9
Profit before exceptional item and tax		543.6	2031.1	841.5	2531.5
Profit after exceptional item and tax		394.8	1615.1	582.5	1157.4
TA wise performance	Oncology	2399.6	7510.9	3158.5	11171.4
	Biopharmaceuticals (CVRM, R&I and V&I)	1204.6	4537.0	1227.4	4881.2
	Rare Disease	1.7	8.5	20.0	31.7

Bhavana Agrawal, Chief Financial Officer & Director of the Company, said, "FY 2024-25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32%. This reflects our strategic focus on science, specialist, and the strength of our innovation-led portfolio. As we scale impact across therapy areas, we remain committed to delivering sustainable value to the people, society and the planet."

Dr. Sanjeev Panchal, Country President & Managing Director of the Company, said, "Our company delivered a strong growth in Financial Year 2024-25 by bringing innovative medicine launches in India, giving us a momentum into 2025 and beyond. We are pleased to share that our company has for the first time crossed the INR 1700 cr mark (\$200 Mn). Science is sustaining and growing the success of our company, helping us transform the future of healthcare, and the health of people, society and the planet."

Key milestones:

- Since 2023, the Company has delivered 14 approvals across its portfolio- Oncology, Biopharmaceutical, Rare Disease.
- In FY '24- '25 the company announced regulatory approvals for:
 - **Palivizumab (50mg/0.5mL):** Following the receipt of approval from Drugs Controller General of India (DCGI) in September 2023, the Company launched Palivizumab (50mg/0.5ml) in October 2024. This monoclonal antibody is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk paediatric patients.
 - **Tremelimumab (25mg/mL):** Following DCGI approval in May 2023, the company launched Tremelimumab in October 2024. Tremelimumab in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).
 - **Durvalumab – Additional Indication (NSCLC):** Secured Central Drugs Standard Control Organization's (CDSCO) approval in September 2024 for an additional indication—neoadjuvant and adjuvant use in resectable NSCLC (tumors ≥ 4 cm and/or node-positive), in combination with chemotherapy and as monotherapy post-surgery.
 - **Olaparib + Durvalumab (Endometrial Cancer):** Received CDSCO approval for the additional indication for the maintenance treatment of adult patients with advanced or recurrent endometrial cancer who have not progressed following first-line treatment with Durvalumab in combination with platinum-based chemotherapy.
 - **Budesonide/Glycopyrronium/Formoterol:** Approved by CDSCO in December 2023 and launched in January 2025, this is indicated for maintenance treatment in adults with chronic obstructive pulmonary disease (COPD) to relieve symptoms and prevent exacerbations.
 - **Eculizumab (300mg/30mL):** Approved for import and distribution by CDSCO, this is indicated for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) to inhibit complement – mediated thrombotic microangiopathy.
 - **Durvalumab – Additional Indication:** Gained CDSCO approval in March 2025 for use of Durvalumab in combination with Tremelimumab for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
 - **Sodium Zirconium Cyclosilicate (5g/10g):** Received CDSCO permission for import and sale in March 2025. This novel oral suspension significantly improves hyperkalaemia management in adults, commonly associated with cardiovascular, renal, and metabolic conditions.
 - **Durvalumab: Additional Indication:** Gained CDSCO approval in March 2025 for use of Durvalumab for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
- **Partnership for Health System Sustainability and Resilience (PHSSR)** commissioned independent report was presented at the Embassy of Sweden in the presence of key dignitaries from the Ministry of Health & Family Welfare, key influencers from the healthcare ecosystem followed by a deep deliberation on how private and public sectors need to jointly prioritise areas of concern that emerged from the COVID-19 pandemic and prepare the Indian health system to tackle crises when needed.

Key Appointments

- **Ms. Monica Widhani** was appointed as an Independent Director on the Board of the Company, with effect from September 25, 2024
- **Ms. Shilpa Divekar Nirula**, Independent Director has been unanimously elected as Chairperson of the Board, effective September 30, 2024
- **Mr. Jesus Javier Diaz Ropero Estes** was appointed as a Non-Executive Director of the Company with effect from November 13, 2024
- Ms. Shikha Mirchandani Chatrath was appointed as Director – Commercial Excellence, BD & Strategy with effect from June 17, 2024
- Mr. Srikanth. B.S. was appointed as the Site-Lead, India Operations with effect from August 1, 2024

- **Ms Amita Bhave** was appointed as Head Regulatory Affairs at the Company with effect from November 18, 2024
- **Dr. Sandeep Arora** was appointed as Director, Medical Affairs with effect from March 3, 2025
- **Harish Dash** was appointed as Senior Director, Commercial IT & Digital with effect from March 3, 2025.

Recognitions:

- The Company was **recognised for a valuable contribution** in spreading **large scale awareness on RSV** in the country at National Neonatology Forum Program - NEOCON 2024
- The Company was awarded a **'Great Place To Work' for the seventh consecutive time**
- The Company was awarded **'ET Now Progressive Company of the year'** for demonstrating an exceptional commitment to workplace excellence and contributing significantly to industry success.
- Recognized as one of **'India's Best Organizations in Innovation' by ET Now**
- Awarded **'Pharma InHouse Legal Team of the Year'** at the 13th Annual Legal Era - Indian Legal Awards 2023-24
- Amarpreet Kaur Ahuja, Country HR Director, was featured among **"The Powerhouses of Indian HR: Women Driving Change and Innovation"** by Indian Conventions
- **Diversity and Inclusion Award 2024** at the 57th OPPI Annual Day
- Awarded **'Silver' for Best Employer for Women in Small Category** at the ASSOCHAM 5th Diversity & Inclusion Excellence Awards & Conclave – 2024

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Completing its 45 years in India, AstraZeneca Pharma India Limited is headquartered at Bengaluru, Karnataka in India and has a workforce of over 600 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: <https://www.astrazeneca.in/> or follow us on LinkedIn: [AstraZeneca India](#).